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Abstract Commercially available antisera against five sub-
types of muscarinic receptors and nine subtypes of
adrenoceptors showed highly distinct immunohistochemical
staining patterns in rat ureter and stomach. However, using
the M1–4 muscarinic receptor subtypes and α2B-, β2-, and
β3-adrenoceptors as examples, Western blots with mem-
branes prepared from cell lines stably expressing various
subtypes of muscarinic receptors or adrenoceptors revealed
that each of the antisera recognized a set of proteins that
differed between the cell lines used but lacked specificity
for the claimed target receptor. We propose that receptor
antibodies need better validation before they can reliably be
used.






The use of antisera for immunohistochemical or other
applications is based on the assumption that they exhibit
high specificity for their target. Many commercially
available antibodies are stated to be “affinity”-purified,
but it is doubtful whether this purification procedure
actually improves their specificity. Among the many criteria
to evaluate specificity, a claim for selectivity of commer-
cially available antisera is most often based upon a distinct
immunohistochemical staining pattern, a single band of the
expected size on Western blots, and/or the disappearance of
staining after pre-absorption of the antiserum with purified
epitope (cf. Petrusz et al. 1976 versus Swaab et al. 1977).
However, all of these are soft criteria with justifiable
exceptions. More meaningful “hard” specificity criteria
include a staining pattern that is identical to that of an
antibody raised against a different epitope on the same protein
(Fischer et al. 2003) or the absence of staining in tissues of
animals genetically deficient for the antigen (Swaab et al.
1977; Holmseth et al. 2006; Pradidarcheep et al. 2008). For
example, we have recently reported that commercially
available antisera against muscarinic receptor subtypes
fulfilling at least one of the “soft” criteria lack specificity
when tested in mice genetically deficient for the target
receptor (Pradidarcheep et al. 2008). Therefore, additional
validation of specificity of antibodies is often required.
Naunyn-Schmied Arch Pharmacol (2009) 379:397–402
DOI 10.1007/s00210-009-0393-0
W. Pradidarcheep
Department of Anatomy, Faculty of Medicine,
Srinakharinwirot University,
Bangkok, Thailand
W. Pradidarcheep : J. Stallen :W. T. Labruyère :
W. H. Lamers (*)
AMC Liver Center, Academic Medical Center,
University of Amsterdam,
Meibergdreef 69-71,
1105 BK Amsterdam, The Netherlands
e-mail: w.h.lamers@amc.uva.nl
N. F. Dabhoiwala




Department of Pharmacology and Pharmacotherapy,
Academic Medical Center, University of Amsterdam,
Amsterdam, The Netherlands
While knockout animals are one of the most elegant
ways to demonstrate specificity of a given antibody, their
routine use for validation has several limitations. Firstly,
knockout animals are not available, at least not for some
researchers wishing to validate their antisera, for all target
proteins. Secondly, an antibody for a given species of
interest may not necessarily cross-react with its murine
homolog. Finally, it is conceivable that a given antiserum
may not be sufficiently specific for use, e.g., in immuno-
histochemistry but may nevertheless be suitable in Western
blotting because band size can be used as an additional
criterion to identify the protein of interest. An example of
this is commercially available antibodies against Gs proteins
which cross-react with smoothelin (Gsell et al. 2000); while
this limits their use in immunohistochemistry, such antisera
have nevertheless been helpful in studying regulation of Gs
proteins by Western blots in many laboratories.
Therefore, we have tested whether genetically modified
cell lines that stably express a receptor subtype of interest
or related subtypes could be an attractive alternative for the
use of knockout animals. Because all antisera against
muscarinic receptors (MR) and adrenoceptors (AR) that were
investigated failed this test and because this finding appears
the rule rather than the exception, we propose to qualify
antisera that meet the “hard” specificity criteria as “validated.”
Materials and methods
Antibodies The antisera that were used are described in
Table 1. All antibodies were designated affinity-purified
preparations by the respective suppliers.
Animals Wistar rats, 4–5 weeks old, were euthanized by
instant decapitation under an O2/CO2 daze, in agreement
with Dutch guidelines for experimental animals.
Immunohistochemical staining The organs of the lower
urinary and gastrointestinal tract were fixed overnight at 4°C
by immersion in an ice-cold mixture of methanol–acetone–
water (2:2:1; v/v). After dehydration and embedding, serial
sections (7 μm) were mounted on poly-L-lysine-coated slides
(for details, see Pradidarcheep et al. 2008). Antibody
concentrations and staining times were chosen to assure a
linear relation between antibody binding and staining
intensity (van Straaten et al. 2006). Control sections, in
which the primary antibody was omitted, were always
included in the assays.
Cell lines expressing adrenergic or muscarinic receptors Cell
lines stably transfected with the human α1A-, α1B-, or α1D-
AR (Rat-1 fibroblasts) or α2A-, α2B-, or α2C-AR (HEK-293
cells; Krege et al. 2000), β1-, β2-, or β3-AR (Chinese
hamster ovary (CHO) cells; Niclauß et al. 2006), or M1-,
M2-, M3-, or M4-MR (HEK-293 cells; Schmidt et al. 1995)
were maintained as previously described. All cell lines had
been tested for the expression of the transfected receptor
subtype based on cell signaling responses or radioligand
binding.
Western blotting The preparation of whole-cell protein
extracts in radioimmunoprecipitation assay buffer contain-
ing protease inhibitors, their separation on sodium dodecyl
sulfate (SDS)-polyacrylamide gels, and blotting to poly-
Table 1 Antibodies used in this study
Antigen Host species Dilution WB Dilution IHC Code Supplier Blocking serum
MR1 Rabbit 1:900 1:300 AMR-001 Alomone Labs Goat or fetal calf
MR2 Rabbit 1:600 1:250 AMR-002 Alomone Labs Goat or fetal calf
MR3 Rabbit 1:750 1:500 AS-3741S RnD Goat or fetal calf
MR4 Mouse 1:300 1:50 MAB1576 Chemicon Fetal calf
MR5 Rabbit 1:1,000 1:1,000 AS-3781S RnD Goat or fetal calf
α1A AR Goat 1:400 1:50 sc-1477 Santa Cruz Rabbit or fetal calf
α1B AR Goat 1:400 1:50 sc-1476 Santa Cruz Rabbit or fetal calf
α1D AR Rabbit 1:400 1:50 sc-10721 Santa Cruz Goat or fetal calf
α2A AR Goat 1:400 1:100 sc-1478 Santa Cruz Rabbit or fetal calf
α2B AR Rabbit 1:400 1:50 sc-10723 Santa Cruz Goat or fetal calf
α2C AR Goat 1:400 1:50 sc-1480 Santa Cruz Fetal calf
β1 AR Rabbit 1:400 1:100 sc-568 Santa Cruz Goat or fetal calf
β2 AR Rabbit 1:400 1:50 sc-9042 Santa Cruz Goat or fetal calf
β3 AR Goat 1:400 1:50 sc-1473 Santa Cruz Rabbit or fetal calf
Mouse IgG Goat 1:3,000 1:100 A-3562 Sigma –
Rabbit IgG Goat 1:1,000 1:50 D-0487 Dako –
Goat IgG Rabbit – 1:50 A-4187 Sigma –
Goat IgG Rabbit 1:2,500 – 172-1037 Biorad –
WB Western blotting, IHC immunohistochemistry
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vinylidene fluoride membranes (Millipore) were exactly as
described (Pradidarcheep et al. 2008). After blocking, the
membranes were exposed overnight to the antisera at the
concentrations described in Table 1. Antibody binding was
visualized with horseradish-peroxidase-conjugated goat
antirabbit or goat antimouse secondary antibody and
chemiluminescent imaging.
Results
Distinct staining patterns, including low
background staining
The staining patterns of five MR and nine AR subtype
antibodies in the organs of the rat lower urinary tract, e.g.,
the ureter (Fig. 1), and the gastrointestinal tract, e.g., the
stomach (Fig. 2), were distinct for each antiserum. Thus,
the cellular staining patterns were different for all MR
antisera. Although the α1A- and α1B-AR staining patterns
of the ureter were similar, these antisera produced distinct
staining patterns in the stomach. Conversely, the α1B-, α1D-,
and α2A-AR antisera produced similar staining patterns in
the stomach but distinct patterns in the ureter. These
findings demonstrate that each of the antisera generated a
staining pattern that differed from all other antisera, with
little or no background noise. Unfortunately, such “pretty”
staining patterns do not, as we will see, predict specificity
for the cognate receptor.
Demonstration of lack of specificity
Western blots with extracts of organs of the lower urinary
tract, gastrointestinal tract, and brain were prepared but the
outcome was not satisfactory because all antisera yielded
too many bands and did not allow specific detection of a
major band likely to represent the target receptor (not
shown). Whole-cell extracts of cell lines each stably
expressing cloned human MR or AR subtypes were used
for further evaluation of the various antisera. While, similar
to the tissue sections, each MR antiserum generated a
distinct “finger print” on the Western blot, that pattern was
similar in cell lines expressing the cognate receptor subtype
or related subtypes (Fig. 3). Similar observations were
made with antisera supposedly acting on α2B-, β2-, or β3-
AR (Fig. 4). These antisera, especially the α2B- and β3-AR
preparations, produced a distinct banding pattern for Rat-1
fibroblasts (α1A-, α1B-, and α1D-AR lanes), HEK-293 cells
(α2A-, α2B-, and α2C-AR lanes), and CHO cells (β1-, β2-,
or β3-AR lanes) rather than a unique band (or set of bands
in case posttranslational modifications had occurred) that
was specific for the receptor that was transfected.
Discussion
In our immunohistochemical experiments, all MR and AR
antisera tested showed tissue- and antiserum-dependent
staining patterns with a very satisfactory signal-to-
background ratio in distinct tissues (Figs. 1 and 2). While
α1A-AR α1B-AR α1D-AR α2B-ARα2A-AR
β 1-AR β 3-ARα2C-AR β 2-AR
M1 M3 M4M2 M5
control
0.1 mm
Fig. 1 Staining for the presence of MR and AR subtypes in the ureter of the rat. Control: section incubated without primary antiserum. Bar=
0.2 mm
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each of the antisera exhibited a distinct pattern of bands
for each host cell line, i.e., Rat-1 vs. CHO vs. HEK-293, in
Western blots, none of them produced a distinct band in
the cells expressing their target receptor as compared to
those expressing related subtypes. While these findings
raise questions about the selectivity of the antisera for their
respective cognate receptors, several caveats need to be
considered.
Firstly, it is possible that a given receptor presents
differently in its native conformation (as seen in immuno-
histochemistry) as compared to the conformation adopted
under denaturing condition (as seen on a SDS gel). While
this means that an antibody lacking specificity on Western
blots does not necessarily lack specificity in immunohisto-
chemistry, our data nevertheless clearly do not support the
idea of specificity. Moreover, transfected cells can of course
α1A - AR α1B - AR α1D - AR α2A - AR α2B - AR
α2C - AR β 1 - AR β 2 - AR β 3 - AR
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Fig. 3 Staining pattern of antisera against MR subtypes on Western
blots of cell lines each expressing one MR. Extracts (50-μg protein) of
cell lines stably transfected with an expression vector encoding the
MR indicated above each lane were electrophoresed, blotted, and
stained for the presence of MR subtypes with the antisera. The
calculated molecular weights for M1, M2, M3, and M4 receptors are 51,
52, 66, and 53 kDa, respectively. Note that each antiserum generated a
unique staining pattern but that the pattern was identical irrespective of
which MR subtype was expressed in the cell line
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also be used to test antibody specificity in immunocyto-
chemistry. Secondly, our comparisons have not been based
on non- or mock-transfected cells but rather on those
transfected with related receptor subtypes. We actually
consider this to be a strength of our approach as a given
receptor upon overexpression may appear selective but
loses that “selectivity” when studied at the lower expression
levels occurring physiologically. This problem is circum-
vented by the use of the same cell line expressing related
subtypes at a similar density. Thirdly, our immunoblots
(based upon whole-cell extracts) show numerous bands for
each antiserum, whereas those shown in a supplier’s catalog
often show a single band only. While the number of bands
due to low-affinity binding to other targets depends on the
specific experimental conditions, any “specific” antibody
should at least identify a unique major band even if the
chosen conditions allow detection of various non-specific
bands. However, that was not the case for any of the
antibodies we have studied. Finally, the possibility should
be considered that a given cell line has lost expression of
the transfected receptor. While this is always a theoretical
possibility, it is extremely unlikely that this applies to all 13
cell lines tested here. Moreover, we have verified the
maintained presence of the transfected gene by cell
signaling and/or radioligand binding studies for most cell
lines within few months of the Western blot experiments.
In summary, we have shown that many receptor anti-
bodies lack specificity for their cognate receptor in Western
blots despite yielding very distinct staining patterns in
tissues. We conclude that traditional criteria for antiserum
specificity such as use of “pre-absorption,” elimination of
staining by pre-incubation with the antigen, or the presence
of only a single band on Western blots do not reliably
predict specificity. While the use of corresponding knock-
out animals or the presence of identical staining patterns of
antisera raised against distinct epitopes are the most reliable
tests of specificity, we propose that the use of cell lines
transfected with the target as compared to related receptors
is a useful alternative to explore the specificity of antisera.
We further propose that antisera, which pass one or both
hard criteria and have this documented in the specification
sheets, be identified as “validated” for easy recognition. It
should be kept in mind, of course, that validation only
assures the user that such an antiserum recognizes the
macromolecule against which it was raised. Nevertheless,
even a validated antiserum can, if applied improperly, still
produce artifacts. The introduction of validated antisera
could, nevertheless, provide the end user with a reliable
starting preparation and, thus, avoid many fruitless and
costly general confirmation assays that should have been
carried out by the supplier. Finally, validated antisera would
also further science by diminishing the scientific noise
α1A α1B α1D α2A α2B α2C β1 β2 β3
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Ab β3-AR
Fig. 4 Staining pattern of antisera against AR subtypes on Western
blots of cell lines each expressing one AR. Extracts (50-μg protein) of
cell lines stably transfected with an expression vector encoding the AR
indicated above each lane were electrophoresed, blotted, and stained
for the presence of the α2B-, β2-, and β3-AR subtypes with the
antisera. The calculated molecular weights for α1A-, α1B-, α1D-, α2A-,
α2B-, α2C-, β1-, β2-, and β3-AR are 52, 56, 59, 50, 50, 50, 50, 47, and
43 kDa, respectively. Note that each antiserum shown generated a
unique staining pattern but that none identified a band of the
anticipated size and that many bands were shared irrespective of
which AR subtype was expressed
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generated by erroneous data like those exposed in this
series of articles.
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